Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 102 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant
Baisheng Li, Aiping Deng, Kuibiao Li, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 443
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Gang Zeng, Qianhui Wu, Hongxing Pan, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 4, pp. 483-495
Open Access | Times Cited: 267
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Baoqi Zeng, Le Gao, Qingxin Zhou, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 234
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
Global landscape of SARS-CoV-2 genomic surveillance and data sharing
Zhiyuan Chen, Andrew S. Azman, Xinhua Chen, et al.
Nature Genetics (2022) Vol. 54, Iss. 4, pp. 499-507
Open Access | Times Cited: 226
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study
Li Guo, Geng Wang, Yeming Wang, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 5, pp. e348-e356
Open Access | Times Cited: 148
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
Khalil El Karoui, An S. De Vriese
Kidney International (2022) Vol. 101, Iss. 5, pp. 883-894
Open Access | Times Cited: 116
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
Philip L. Tzou, Kaiming Tao, Sergei L. Kosakovsky Pond, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0261045-e0261045
Open Access | Times Cited: 93
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
Zhirong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 89
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Levente Zsichla, Viktor Müller
Viruses (2023) Vol. 15, Iss. 1, pp. 175-175
Open Access | Times Cited: 66
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
Felipe Melo-González, Jorge A. Soto, Liliana A González, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 76
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Mengxin Zhang, Ying Liang, Dongsheng Yu, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 2, pp. 889-900
Open Access | Times Cited: 60
SARS-CoV-2 variants – Evolution, spike protein, and vaccines
Kai-Wei K. Chen, Daniel Tsung‐Ning Huang, Li‐Min Huang
Biomedical Journal (2022) Vol. 45, Iss. 4, pp. 573-579
Open Access | Times Cited: 49
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Laurent Rénia, Yun Shan Goh, Angéline Rouers, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
Yubin Liu, Ziyi Wang, Xinyu Zhuang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Dima Hattab, Mumen F. A. Amer, Zina M. Al‐Alami, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 767-786
Open Access | Times Cited: 13
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
Chloé Dimeglio, Marion Migueres, Naémie Bouzid, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1548-1548
Open Access | Times Cited: 36
Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern
Jian Wang, Yu Wen, Shihao Zhou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 2558-2570
Closed Access | Times Cited: 35
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Elizabeth M. Anderson, Shuk Hang Li, Moses Awofolaju, et al.
Cell Reports (2022) Vol. 41, Iss. 3, pp. 111496-111496
Open Access | Times Cited: 35
A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days
Xianming Liang, Qiu‐Yan Xu, Zhi-Juan Jia, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya Menon, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 1, pp. 23-34
Open Access | Times Cited: 33
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6272-6272
Open Access | Times Cited: 33
Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
Wei Zhao, Weixin Chen, Juan Li, et al.
mBio (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top